The in vitro and in vivo efficacy of fluconazole in combination with farnesol against Candida albicans isolates using a murine vulvovaginitis model

다국어 초록 (Multilingual Abstract)

Farnesol is a quorum-sensing molecule that inhibits biofilm formation in Candida albicans. Previous in vitro data suggest that, in combination with certain antifungals, farnesol may have an adjuvant anti-biofilm agent. However, the in vivo efficacy of farnesol is very questionable. Therefore, the in vitro and in vivo activity of fluconazole combined with farnesol was evaluated against C. albicans biofilms using fractional inhibitory concentration index (FICI) determination, time-kill experiments and a murine vulvovaginitis model.
The median biofilm MICs of fluconazole-sensitive C. albicans isolates ranged between 4 -> 512 mg/L and 150–300 μM for fluconazole and farnesol, respectively. These values were 512 -> 512 mg/L and > 300 μM for fluconazole-resistant clinical isolates. Farnesol decreased the median MICs of fluconazole by 2-64-fold for biofilms. Based on FICI, synergistic interaction was observed only in the case of the sessile SC5314 reference strain (FICIs: 0.16–0.27). In time-kill studies, only the 512 mg/L fluconazole and 512 mg/L fluconazole + 75 μM farnesol reduced biofilm mass significantly at each time point in the case of all isolates. The combination reduced the metabolic activity of biofilms for all isolates in a concentration- and time-dependent manner. Our findings revealed that farnesol alone was not protective in a murine vulvovaginitis model. Farnesol was not beneficial in combination with fluconazole for fluconazole-susceptible isolates, but partially increased fluconazole activity against one fluconazole- resistant isolate, but not the other one.

참고문헌 (Reference)

1 Pfaller, M. A., "Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods" 13 : 180-195, 2010

2 González, G. M., "Therapeutic efficacy of posaconazole against isolates of Candida albicans with different susceptibilities to fluconazole in a vaginal model" 45 : 221-224, 2007

3 Sharma, M., "The quorum-sensing molecule farnesol is a modulator of drug efflux mediated by ABC multidrug transporters and synergizes with drugs in Candida albicans" 55 : 4834-4843, 2011

4 Han, T. L., "The metabolic response of Candida albicans to farnesol under hyphae-inducing conditions" 12 : 879-889, 2012

5 Kovács, R., "Serum interleukin-6 levels in murine models of Candida albicans infection" 61 : 61-69, 2014

6 Clinical and Laboratory Standards Institute, "Reference method for broth dilution antifungal susceptibility testing of yeasts"

7 Hornby, J. M., "Quorum sensing in the dimorphic fungus Candida albicans is mediated by farnesol" 67 : 2982-2992, 2001

8 Hisajima, T., "Protective effects of farnesol against oral candidiasis in mice" 52 : 327-333, 2008

9 Ganguly, S., "Mucosal biofilms of Candida albicans" 14 : 380-385, 2011

10 Cordeiro, R. A., "Minimum inhibitory concentrations of amphotericin B, azoles and caspofungin against Candida species are reduced by farnesol" 51 : 53-59, 2013

11 O’Toole, G. A., "Microtiter dish biofilm formation assay" 47 : 2437-, 2011

12 Louie, A., "Interaction between fluconazole and amphotericin B in mice with systemic infection due to fluconazole-susceptible or -resistant strains of Candida albicans" 43 : 2841-2847, 1999

13 Ramage, G., "Inhibition of Candida albicans biofilm formation by farnesol, a quorum-sensing molecule" 68 : 5459-5463, 2002

14 Katragkou, A., "In vitro interactions between farnesol and fluconazole, amphotericin B or micafungin against Candida albicans biofilms" 70 : 470-478, 2015

15 Zhou, Y., "In vitro interactions between aspirin and amphotericin B against planktonic cells and biofilm cells of Candida albicans and C. parapsilosis" 56 : 3250-3260, 2012

16 Hornby, J.M., "Enhanced production of farnesol by Candida albicans treated with four azoles" 48 : 2305-2307, 2004

17 Elizondo-Zertuche, M., "Efficacy of ravuconazole in a murine model of vaginitis by Candida albicans" 32 : 30-33, 2015

18 Fidel, P. L. Jr., "Effects of reproductive hormones on experimental vaginal candidiasis" 68 : 651-657, 2000

19 Navarathna, D. H., "Effect of farnesol on a mouse model of systemic candidiasis, determined by use of a DPP3 knockout mutant of Candida albicans" 75 : 1609-1618, 2007

20 Jabra-Rizk, M. A., "Effect of farnesol on Candida dubliniensis biofilm formation and fluconazole resistance" 6 : 1063-1073, 2006

21 Martins, M., "Effect of exogenous administration of Candida albicans autoregulatory alcohols in a murine model of hematogenously disseminated candidiasis" 52 : 487-491, 2012

22 Kovács, R., "Effect of caspofungin and micafungin in combination with farnesol against Candida parapsilosis biofilms" 47 : 304-310, 2016

23 Uppuluri, P., "Dispersion as an important step in the Candida albicans biofilm developmental cycle" 6 : e1000828-, 2010

24 Hawser, S., "Comparisons of the susceptibilities of planktonic and adherent Candida albicans to antifungal agents: a modified XTT tetrazolium assay using synchronised C. albicans cells" 34 : 149-152, 1996

25 De Cremer, K., "Combinatorial drug approaches to tackle Candida albicans biofilms" 13 : 973-984, 2015

26 Langford, M. L., "Cellular interactions of farnesol, a quorum-sensing molecule produced by Candida albicans" 4 : 1353-1362, 2009

27 Harriott, M. M., "Candida albicans forms biofilms on the vaginal mucosa" 156 : 3635-3644, 2010

28 Meletiadis, J., "Assessing in vitro combinations of antifungal drugs against yeasts and filamentous fungi: comparison of different drug interaction models" 43 : 133-152, 2005

29 Pierce, C. G., "Antifungal therapy with an emphasis on biofilms" 13 : 726-730, 2013

30 Pierce, C. G., "A simple and reproducible 96-well plate-based method for the formation of fungal biofilms and its application to antifungal susceptibility testing" 3 : 1494-1500, 2008